Array BioPharma’s Melanoma Candidate Meets Primary Endpoint

December 22, 2015

Array BioPharma’s binimetinib met the primary endpoint of improved progression-free survival in a Phase 3 study in patients with advanced NRAS-mutant melanoma.

Median PFS on the binimetinib arm was 2.8 months versus 1.5 months on comparator dacarbazine. Binimetinib also is being studied in Phase 3 trials in BRAF-mutant melanoma and ovarian cancer.

Array plans to submit an NDA during the first half of 2016.